Ovarian Cancer Opportunity Assessment Report 2024: A Blockbuster Market that is Expected to Grow from $3.3 Billion in 2022 to $4.1 Billion in 2032 with ImmunoGen, AstraZeneca, Merck, & GSK Dominating
April 09, 2024 07:02 ET
|
Research and Markets
Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The "Ovarian Cancer Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.Ovarian Cancer is one of the most...
Global Gynecological Cancer Drugs Market Report 2022: Advancement of Cancer Drug Research and the Advent of Personalized Medicine Presents Opportunities
August 25, 2022 05:53 ET
|
Research and Markets
Dublin, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The "Gynecological Cancer Drugs Market By Therapeutic Modality, By Indication: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been...
Next-Generation Gynecological Cancer Diagnostics Market Size is projected to reach USD 5.45 Billion by 2030, growing at a CAGR of 10.68%: Straits Research
August 15, 2022 13:50 ET
|
Straits Research
New York, United States, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Uterine, ovarian, and cervical cervix cancers are the most common in women. Cervical cancer ranks fourth among women's...
World Next-Generation Gynecological Cancer Diagnostics Market Research Report 2022 Featuring Laboratory Corp of America, F. Hoffmann-La Roche, Illumina, Agilent Technologies, BGI, and PerkinElmer
April 28, 2022 04:43 ET
|
Research and Markets
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "Next-Generation Gynecological Cancer Diagnostics Market - A Global Market and Regional Analysis: Focus on Technology, Product Type, End User, and...
$31+ Billion Worldwide Gynecology Drugs Industry to 2030 - Identify Growth Segments for Investment
November 11, 2021 06:53 ET
|
Research and Markets
Dublin, Nov. 11, 2021 (GLOBE NEWSWIRE) -- The "Gynecology Drugs Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. This report...
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
November 20, 2017 07:00 ET
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker statusApproval supported by robust data from a randomized,...